An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

References

• Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Int Med. 1993;118:179–184.
   PubMed Web of Science ®Google Scholar
• Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173–178.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Sanz J, Cantero S, et al. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2009;15:730–740.
   PubMed Web of Science ®Google Scholar
• Ordemann R, Naumann R, Geissler G, et al. Foscarnet–an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation? Ann Hematol. 2000;79:432–436.
   PubMed Web of Science ®Google Scholar
• Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99:1159–1164.
   PubMed Web of Science ®Google Scholar
• Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23:689–712.
   PubMed Web of Science ®Google Scholar
• Maffini E, Giaccone L, Festuccia M, et al. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 2016;9:585–596.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011;121:1673–1680.
   PubMed Web of Science ®Google Scholar
• Kaminski H, Fishman JA. The cell biology of cytomegalovirus: implications for transplantation. Am J Transplant. 2016;16:2254–2269.
   PubMed Web of Science ®Google Scholar
• Ligat G, Cazal R, Hantz S, et al. The human cytomegalovirus terminase complex as an antiviral target: a close-up view. FEMS Microbiol Rev. 2018;42:137–145.
   PubMed Web of Science ®Google Scholar
• Melendez-Munoz R, Marchalik R, Jerussi T, et al. Cytomegalovirus infection incidence and risk factors across diverse hematopoietic cell transplantation platforms using a standardized monitoring and treatment approach: a comprehensive evaluation from a single institution. Biol Blood Marrow Transplant. 2019;25(3):577–586.
   PubMedGoogle Scholar
• Jaing T-H, Chang T-Y, Chen S-H, et al. Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation. Medicine (Baltimore). 2019;98:e14172.
   PubMed Web of Science ®Google Scholar
• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127:2427–2438.
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3:e119–127.
   PubMed Web of Science ®Google Scholar
• Meesing A, Razonable RR. New developments in the management of cytomegalovirus infection after transplantation. Drugs. 2018;78:1085–1103.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711–5719.
   PubMed Web of Science ®Google Scholar
• El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016;128:2624–2636.
   PubMed Web of Science ®Google Scholar
• Stoelben S, Arns W, Renders L, et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int. 2014;27:77–86.
   PubMed Web of Science ®Google Scholar
• Yahav D, Gafter-Gvili A, Muchtar E, et al. Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur J Cancer. 2009;45:3131–3148.
   PubMed Web of Science ®Google Scholar
• Marchetti S, Santangelo R, Manzara S, et al. Comparison of real-time PCR and pp65 antigen assays for monitoring the development of cytomegalovirus disease in recipients of solid organ and bone marrow transplants. New Microbiol. 2011;34:157–164.
   PubMed Web of Science ®Google Scholar
• Lilleri D, Gerna G, Furione M, et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood. 2007;110:2757–2760.
   PubMed Web of Science ®Google Scholar
• Gerna G, Lilleri D, Caldera D, et al. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2008;41:873–879.
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamashita T, Mori T, et al. A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT. Bone Marrow Transplant. 2010;45:1325–1332.
   PubMed Web of Science ®Google Scholar
• Lisboa LF, Asberg A, Kumar D, et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation. 2011;91:231–236.
   PubMed Web of Science ®Google Scholar
• Garrigue I, Doussau A, Asselineau J, et al. Prediction of Cytomegalovirus (CMV) plasma load from evaluation of CMV whole-blood load in samples from renal transplant recipients. J Clin Microbiol. 2008;46:493.
   PubMed Web of Science ®Google Scholar
• Lazzarotto T, Chiereghin A, Piralla A, et al. Cytomegalovirus and Epstein–Barr virus DNA kinetics in whole blood and plasma of allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24:1699–1706.
   PubMedGoogle Scholar
• Costa C, Sidoti F, Mantovani S, et al. Comparison of two molecular assays for detection of cytomegalovirus DNA in whole blood and plasma samples from transplant recipients. New Microbiol. 2016;39:186–191.
   PubMed Web of Science ®Google Scholar
• Vinuesa V, Giménez E, Solano C, et al. Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients. Diagn Microbiol Infect Dis. 2019;94:22–27.
   PubMed Web of Science ®Google Scholar
• Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260-e272.
   Web of Science ®Google Scholar
• Solano C, Giménez E, Piñana JL, et al. When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients? Bone Marrow Transplant. 2017;52:1448–1451.
   PubMedGoogle Scholar
• Lilleri D, Lazzarotto T, Ghisetti V, et al. Multicenter quality control study for human cytomegalovirus DNAemia quantification. New Microbiol. 2009;32:245–253.
   PubMed Web of Science ®Google Scholar
• Melendez DP, Razonable RR. Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infect Drug Resist. 2015;8:269–277.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–2444.
   PubMed Web of Science ®Google Scholar
• Fryer JF, Heath AB, Anderson R, et al. Collaborative study to evaluate the proposed 1st [first] WHO international standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays; 2010 [cited 2019 Apr 1]. Available from: https://apps.who.int/iris/handle/10665/70521
   Google Scholar
• Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103:2003–2008.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Labopin M, Beelen D, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Blood. 2013;122:3359–3364.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Brand R, Hoek J, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis. 2014;59:473–481.
   PubMed Web of Science ®Google Scholar
• Navarro D, Amat P, de la Cámara R, et al. Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients. Open Forum Infect Dis. 2016;3:ofw107.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407–414.
   PubMed Web of Science ®Google Scholar
• Yong MK, Lewin SR, Manuel O. Immune Monitoring for CMV in Transplantation. Curr Infect Dis Rep. 2018;20:4.
   PubMed Web of Science ®Google Scholar
• Tey S-K, Kennedy GA, Cromer D, et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS ONE. 2013;8:e74744.
   PubMed Web of Science ®Google Scholar
• Bono P, Orlandi A, Zoccoli A, et al. Quantiferon CMV assay in allogenic stem cell transplant patients. J Clin Virol. 2016;79:10–11.
   PubMed Web of Science ®Google Scholar
• Nesher L, Shah DP, Ariza-Heredia EJ, et al. Utility of the enzyme-linked immunospot interferon-γ-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients. J Infect Dis. 2016;213:1701–1707.
   PubMed Web of Science ®Google Scholar
• Yong MK, Cameron PU, Slavin M, et al. Identifying cytomegalovirus complications using the quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2017;215:1684–1694.
   PubMed Web of Science ®Google Scholar
• Paouri B, Soldatou A, Petrakou E, et al. Quantiferon-cytomegalovirus assay: a potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients. Pediatr Transplant. 2018;22:e13220.
   PubMed Web of Science ®Google Scholar
• Costa C, Balloco C, Sidoti F, et al. Evaluation of CMV-specific cellular immune response by EliSPOT assay in kidney transplant patients. J Clin Virol. 2014;61:523–528.
   PubMed Web of Science ®Google Scholar
• Ciáurriz M, Beloki L, Zabalza A, et al. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients. Transplant Infect Dis. 2017;19:e12778.
   Web of Science ®Google Scholar
• Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56:817–824.
   PubMed Web of Science ®Google Scholar
• Kumar D, Mian M, Singer L, et al. An Interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation. Am J Transplant. 2017;17:2468–2473.
   PubMed Web of Science ®Google Scholar
• De Gracia-Guindo MDC, Ruiz-Fuentes MDC, Galindo-Sacristán P, et al. Cytomegalovirus infection monitoring based on interferon gamma release assay in kidney transplantation. Transplant Proc. 2018;50:578–580.
   PubMed Web of Science ®Google Scholar
• Gliga S, Korth J, Krawczyk A, et al. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients. J Clin Virol. 2018;105:91–96.
   PubMed Web of Science ®Google Scholar
• Chiereghin A, Potena L, Borgese L, et al. Monitoring of cytomegalovirus (CMV)-specific cell-mediated immunity in heart transplant recipients: clinical utility of the quantiFERON-CMV assay for management of posttransplant CMV infection. J Clin Microbiol. 2018;56(4):e01040-17.
   Web of Science ®Google Scholar
• Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, et al. Diagnostic utility of monitoring cytomegalovirus-specific immunity by quantiFERON-cytomegalovirus assay in kidney transplant recipients. BMC Infect Dis. 2018;18:179.
   PubMed Web of Science ®Google Scholar
• Marshall WL, Badshah C, Liu F, et al. No evidence of a drug-drug interaction between letermovir (MK-8228) and mycophenolate mofetil. Biol Blood Marrow Transplant. 2015;21:S243.
   Web of Science ®Google Scholar
• Marshall WL, McCrea JB, Macha S, et al. Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (Posaconazole or Voriconazole) in healthy subjects. J Clin Pharmacol. 2018;58:897–904.
   PubMed Web of Science ®Google Scholar
• Kropeit D, Richter OV, Stobernack H-P, et al. Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects. Clin Pharmacol Drug Dev. 2018;7:9–21.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370:1781–1789.
   PubMed Web of Science ®Google Scholar
• Jung S, Michel M, Stamminger T, et al. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient. BMC Infect Dis. 2019;19:388.
   PubMed Web of Science ®Google Scholar
• Cherrier L, Nasar A, Goodlet KJ, et al. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant. 2018;18:3060–3064.
   PubMed Web of Science ®Google Scholar
• Chou S. Rapid In Vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother. 2015;59:6588–6593.
   PubMed Web of Science ®Google Scholar
• Chou S, Satterwhite LE, Ercolani RJ. New locus of drug resistance in the human cytomegalovirus UL56 gene revealed by In Vitro exposure to letermovir and ganciclovir. Antimicrob Agents Chemother. 2018;62(9):e00922-18.
   Web of Science ®Google Scholar
• Restelli U, Croce D, Pacelli V, et al. Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy. Infect Drug Resist. 2019;12:1127–1138.
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Chemaly RF, et al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25:369–381.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11:284–292.
   PubMed Web of Science ®Google Scholar
• Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis. 2018;68(8):1255–1264.
   PubMed Web of Science ®Google Scholar
• Dole K, Segal FP, Feire A, et al. A first-in-human study to assess the safety and pharmacokinetics of monoclonal antibodies against human cytomegalovirus in healthy volunteers. Antimicrob Agents Chemother. 2016;60:2881–2887.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12:290–299.
   PubMed Web of Science ®Google Scholar
• Incorporated V. Astellas and vical announce top-line results for phase 3 trial of cytomegalovirus vaccine ASP0113 in hematopoietic stem cell transplant recipients [Internet]. GlobeNewswire News Room; 2018 [cited 2019 Apr 14]. Available from: http://www.globenewswire.com/news-release/2018/01/22/1298208/0/en/Astellas-and-Vical-Announce-Top-Line-Results-for-Phase-3-Trial-of-Cytomegalovirus-Vaccine-ASP0113-in-Hematopoietic-Stem-Cell-Transplant-Recipients.html
   Google Scholar
• Nakamura R, La Rosa C, Longmate J, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016;3:e87–98.
   PubMed Web of Science ®Google Scholar
• La Rosa C, Longmate J, Lingaraju CR, et al. Rapid acquisition of cytomegalovirus-specific T cells with a differentiated phenotype, in nonviremic hematopoietic stem transplant recipients vaccinated with CMVPepVax. Biol Blood Marrow Transplant. 2019;25(4):771–784.
   PubMed Web of Science ®Google Scholar
• Ma CKK, Clancy L, Simms R, et al. Adjuvant peptide pulsed dendritic cell vaccination in addition to T cell adoptive immunotherapy for cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24:71–77.
   PubMed Web of Science ®Google Scholar
• Walsh SR, Wilck MB, Dominguez DJ, et al. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis. 2013;207:1888–1897.
   PubMed Web of Science ®Google Scholar
• La Rosa C, Longmate J, Martinez J, et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. Blood. 2017;129:114–125.
   PubMed Web of Science ®Google Scholar
• Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238–241.
   PubMed Web of Science ®Google Scholar
• Blyth E, Clancy L, Simms R, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013;121:3745–3758.
   PubMed Web of Science ®Google Scholar
• Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119:2644–2656.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Verfuerth S, Pizzey A, et al. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis. 2009;49:1851–1860.
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116:4360–4367.
   PubMed Web of Science ®Google Scholar
• Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121:5113–5123.
   PubMed Web of Science ®Google Scholar
• Withers B, Blyth E, Clancy LE, et al. Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. Blood Adv. 2017;1:2193–2205.
   PubMed Web of Science ®Google Scholar
• Neuenhahn M, Albrecht J, Odendahl M, et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia. 2017;31:2161–2171.
   PubMed Web of Science ®Google Scholar
• Pei X-Y, Zhao X-Y, Chang Y-J, et al. Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus. J Infect Dis. 2017;216:945–956.
   PubMed Web of Science ®Google Scholar
• Blyth E, Withers B, Clancy LE, et al. 3rd party CMV-specific T cells provide long term protection against episodes of recurrent CMV after allogeneic stem cell transplant despite lack of persistence in peripheral blood. Blood. 2017;130:1919.
   Google Scholar
• Martins JP, Andoniou CE, Fleming P, et al. Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation. Science. 2019;363:288–293.
   PubMed Web of Science ®Google Scholar